VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2019 | GRIFFIN update: depth of response to D-RVd in transplant eligible NDMM

Peter Voorhees, MD, Levine Cancer Institute, Atrium Health, Charlotte, NC, gives an update on the GRIFFIN study (NCT02874742). This phase 2 randomized trial evaluated daratumumab plus lenalidomide, bortezomib and dexamethasone (RVd) in autologous stem cell transplant eligible newly diagnosed multiple myeloma (NDMM) patients. The data demonstrated that adding daratumumab to RVd significantly improved response rates and depth of response, including stringent complete response and MRD negativity. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter